Stock 6575 SYNEURX INTERNATIONAL (TAIWAN) CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials SyneuRx International (Taiwan) Corp.

Equities

6575

TW0006575004

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 04:30:00 06/01/2023 am IST 		5-day change 1st Jan Change
17.2 TWD -.--% Intraday chart for SyneuRx International (Taiwan) Corp. -.--% -.--%
29/04 SyneuRx International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 SyneuRx International Corp. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5,548 4,957 5,031 5,935 2,083 2,327
Enterprise Value (EV) 1 5,313 4,748 4,793 5,616 2,034 2,239
P/E ratio -27.1 x -21.8 x -22.9 x -18.1 x -5.89 x -17.1 x
Yield - - - - - -
Capitalization / Revenue - - - - - 1,75,99,43,695 x
EV / Revenue - - - - - 1,69,35,94,981 x
EV / EBITDA -25.7 x -22.3 x -23.9 x -18.4 x -6.63 x -16.2 x
EV / FCF -37.7 x -45 x -43.2 x -27.4 x -14.6 x -35.3 x
FCF Yield -2.65% -2.22% -2.32% -3.65% -6.84% -2.83%
Price to Book 16.2 x 16.9 x 16.2 x 13.8 x 21.4 x 21.9 x
Nbr of stocks (in thousands) 1,02,414 1,05,914 1,10,446 1,20,879 1,21,089 1,35,270
Reference price 2 54.17 46.80 45.55 49.10 17.20 17.20
Announcement Date 30/04/19 28/04/20 10/03/21 08/04/22 28/04/23 29/04/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - 1.322
EBITDA 1 -206.4 -212.8 -200.8 -304.6 -307 -138
EBIT 1 -217.1 -223.7 -211.9 -315.3 -310 -139.2
Operating Margin - - - - - -10,529.88%
Earnings before Tax (EBT) 1 -203.7 -224.3 -222.5 -315.3 -348.6 -136.5
Net income 1 -204.4 -223.5 -219.3 -314.9 -353.1 -132.6
Net margin - - - - - -10,026.55%
EPS 2 -1.996 -2.143 -1.992 -2.718 -2.919 -1.004
Free Cash Flow 1 -140.9 -105.5 -111 -205.1 -139.1 -63.36
FCF margin - - - - - -4,792.41%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 30/04/19 28/04/20 10/03/21 08/04/22 28/04/23 29/04/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 235 208 238 319 48.6 87.7
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -141 -106 -111 -205 -139 -63.4
ROE (net income / shareholders' equity) -46% -70.2% -72.6% -85.3% -133% -130%
ROA (Net income/ Total Assets) -28.8% -40.4% -40.2% -47.8% -58.8% -54.3%
Assets 1 709.3 553.1 545.1 658.2 600.5 244.1
Book Value Per Share 2 3.340 2.780 2.810 3.550 0.8000 0.7800
Cash Flow per Share 2 1.050 0.6100 0.4500 1.870 0.6400 0.7500
Capex 1 0.61 0.09 3.29 0.38 1.38 0.57
Capex / Sales - - - - - 43.19%
Announcement Date 30/04/19 28/04/20 10/03/21 08/04/22 28/04/23 29/04/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SYNEURX INTERNATIONAL (TAIWAN) CORP. Stock SyneuRx International (Taiwan) Corp.
-.--% 71.52M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.45% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.96% 116B
ARGENX SE Stock argenx SE
+23.73% 27.03B
BIONTECH SE Stock BioNTech SE
-20.05% 20.36B
BEIGENE, LTD. Stock BeiGene, Ltd.
-16.28% 15.91B
GENMAB A/S Stock Genmab A/S
-16.52% 16.43B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.6B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.91% 14.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.52% 13.59B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6575 Stock
  4. Financials SyneuRx International (Taiwan) Corp.